Logo Image
|Slideshows|February 2, 2017

Antipsychotic Augmentation vs Monotherapy in Schizophrenia

To augment or not to augment? That is the question.

View the slides in PDF format. Also see: Antipsychotics and Breast Cancer Risk.

Related Content

Latest CME

Jersey City Psychiatry
In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Register now!
Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care
Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

View more
Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder
Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

View more
Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia
Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

View more
Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia
Video

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Gus Alva, MD, DFAPA; Erin Crown, MHS, PA-C

View more